A questionnaire-based study to comprehensively assess the status quo of rare disease patients in China

Xuefeng Li, Meiling Liu, Bingzhe Li, Xiangyu Zhang, Shu Zhang, Zijuan Lu, Jianyong Zhang, Jincheng Zhou, Li OuResearch Square 2020 · DOI

Abstract

With over 16.8 million rare disease patients in China, there is an urgent need for data-driven policy to address their unmet needs. This study utilized a comprehensive questionnaire-based approach to analyze the status quo of 1,959 patients and caregivers across 104 rare diseases. Findings reveal significant diagnostic delays, extreme geographic inequality in medical resources, and a heavy socioeconomic and psychological burden. Standardized health assessments (SF-36, PHQ-9, etc.) showed significantly poorer health and mental well-being compared to healthy populations. The study recommends legislative action, such as an Orphan Drug Act, to improve awareness and support for this community.

Introduction

Rare diseases affect an estimated 6–10% of the global population. In China, the absence of a formal legal definition and specific legislation for rare diseases has left millions of patients in a precarious position. This study addresses the critical data gap regarding the "diagnostic odyssey," financial insolvency, and psychological health of these individuals and their families to provide an empirical basis for future legislation regarding orphan drug development and medical insurance.

Methods and Participants

The researchers conducted a cross-sectional study using a 116-question survey distributed between March and May 2020. The cohort included 1,959 participants representing 104 rare diseases, including Congenital Adrenal Hyperplasia (CAH), Phenylketonuria (PKU), and Hemophilia.

Demographic breakdown of the study participants, including gender, age, and geographic distribution.

The study employed five validated clinical instruments: SF-36 (general health), PHQ-9 (depression), PHQ-15 (somatic symptoms), GAD-7 (anxiety), and PSQI (sleep quality). Data were analyzed using a General Linear Model (GLM) to identify key predictors of health outcomes.

Key Insights

Geographic Inequality and the "Big City" Bottleneck

A primary finding was the extreme centralization of medical expertise. Nearly 44% of diagnoses occurred in just 10 hospitals, and 42% were concentrated in five major cities. This geographic disparity forces patients from rural provinces to travel vast distances, often at great expense, to receive specialized care.

The Newborn Screening Advantage

Contrary to the 5–7 year diagnostic delay often reported in Western literature, this cohort experienced an average delay of 1.4 years. This improvement is largely attributed to China's expanding newborn screening programs, which identified 26.1% of the cases in this study.

Key Results: Health and Socioeconomic Impact

The psychological and physical toll on both patients and caregivers is severe. Patients reported moderate depression (PHQ-9 average of 12.1) and mild-to-moderate anxiety (GAD-7 average of 9.0), compared to healthy normative values of approximately 3.0.

Comparison of SF-36 health domain scores between patients, caregivers, and normative healthy populations in China and North America.

As shown in the table above, patients scored significantly lower across all SF-36 domains—particularly in "Role Physical" (26.8) and "Social Functioning" (33.3)—compared to healthy benchmarks. Caregivers also exhibited higher-than-normal levels of distress, highlighting that a rare disease is a "family diagnosis."

Socioeconomically, the burden is equally heavy. Over 12% of families spent more than their entire annual income on medical costs, and nearly half (48.1%) had no insurance coverage for their specific disease. Furthermore, only 4.7% of patients held full-time employment, and nearly 60% faced significant barriers to education.

Conclusion and Recommendations

The study identifies a lack of awareness and legislative support as the primary challenges facing the rare disease community in China. The authors call for the establishment of a National Rare Disease Registry and the urgent passage of an Orphan Drug Act to incentivize local R&D and improve the affordability of life-saving treatments. Addressing these systemic issues is essential to protecting the rights and health of millions of citizens.

Summary updated

Abstract

<title>Abstract</title> <bold>Background</bold>: There are over 16.8 million rare disease patients in China, representing a large community that should not be neglected. To provide a basis for policy-makers, a comprehensive analysis of the status quo, unmet needs, difficulty caused by the rare disease is essential.<bold>Methods</bold>: Therefore, a questionnaire-based study of patients and care-givers was performed.<bold>Findings</bold>: A total of 1,959 patients and care-givers participated, representing 104 rare diseases, such as lysosomal diseases, hemophilia, and muscular dystrophy. The diagnosis was delayed for 1.4 ± 3.0 years, and patients experienced 1.6 ± 3.8 misdiagnoses between 3.2 ± 2.4 hospitals. The hospitals where diagnoses made were highly concentrated in 10 large hospitals (43.8%) and 5 big cities (42.1%), indicating a significant inequality of medical resources. The disease often led to difficulty in social life, education, and employment, as well as financial burden that was seldom covered by medical insurance. A battery of standardized tests, including SF-36, PHQ-9, PHQ-15, GAD-7, and PSQI, demonstrated poor health status, depression, somatization, anxiety, and sleeping issues among both patients and care-givers (p&lt;0.05).To examine the influence of age, disease type, and relationship to patients on the scores in these tests, statistical analysis with a general linear model was conducted. It was also shown that poor health, anxiety, depression, somatization, and sleeping problems were more prevalent in patients than in care-givers, and more prevalent in more severe diseases (e.g., hemophilia, Dravet) or undiagnosed than in other diseases.<bold>Interpretations</bold>: This study identified the lack of rare disease awareness and legislative support as the major challenge to rare diseases in China, and makes key recommendations for policy-makers, including legislating orphan drug act, raising rare disease awareness, and protecting rights in education and employment.
BibTeX
@inproceedings{li2020questionnaire,
  author = {Xuefeng Li and Meiling Liu and Bingzhe Li and Xiangyu Zhang and Shu Zhang and Zijuan Lu and Jianyong Zhang and Jincheng Zhou and Li Ou},
  title = {{A questionnaire-based study to comprehensively assess the status quo of rare disease patients in China}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.3.rs-88844/v1},
}
Figure